Tag - Matthew Kaplan

Markets

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...

January 22, 2020

Markets

Ladenburg cuts Anchiano Therapeutics to neutral and removes PT

Ladenburg Thalmann downgraded Anchiano Therapeutics (NASDAQ:ANCN) to “neutral” from “buy” without a price target after the company discontinued its Phase 2 Codex program to focus on its preclinical pan-RAS inhibitor...

November 18, 2019

Tag - Matthew Kaplan

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg cuts Anchiano Therapeutics to neutral and removes PT

General

More